Beyond breast specific—Graded Prognostic Assessment in patients with brain metastases from breast cancer: treatment impact on outcome
Gaia Griguolo(University of North Carolina at Chapel Hill), Valentina Guarneri(Istituto Oncologico Veneto), Cristina Ghiotto(Istituto Oncologico Veneto), Giulia Tasca(University of Padua), PierFranco Conte(University of Padua), Tommaso Giarratano(Istituto Oncologico Veneto), Alessandro Della Puppa(Azienda Ospedale - Università Padova), Franco Berti(Istituto Oncologico Veneto), Enrico Orvieto(AULSS 2 Marca Trevigiana), Nicola Milite(University of Padua), Maria Vittoria Dieci(Istituto Oncologico Veneto), Carlo Alberto Giorgi(Istituto Oncologico Veneto), Cristina Falci(Istituti di Ricovero e Cura a Carattere Scientifico), Eleonora Mioranza(Istituti di Ricovero e Cura a Carattere Scientifico), Renato Scienza(Azienda Ospedale - Università Padova), Federica Miglietta(University of Padua)
Cited by 8
Related Papers
Gemcitabine and Cisplatin Versus Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Advanced or Metastatic Bladder Cancer: Results of a Large, Randomized, Multinational, Multicenter, Phase III Study
|Journal of Clinical Oncology|2000|2.3k
Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group.
|IRIS UNIMORE (University of Modena and Reggio Emilia)|2005|1.6k
The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor–Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy—MONARCH 2
|JAMA Oncology|2019|983
Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
|Annals of Oncology|2023|830